The heterogeneity of low passage human cytomegalovirus (HCMV) strains was determined by HindlII typing of 28 clinical isolates from transplant patients. These data have shown that, in general, each patient's strain has a unique restriction profile, usually comprising combinations of HindlII sites present in one or more of the tissue culture-adapted strains AD169, Towne and Davis. To map sequence changes in a more refined manner we performed detailed analyses of 33 low passage clinical isolates, including those aforementioned, analysing a sequence within glycoprotein B containing a major neutralizing epitope. A 149 bp sequence containing the epitope (amino acids 608 to 625) was amplified using the polymerase chain reaction, the products were cloned and their DNA sequence was determined. Comparison of the DNA and deduced amino acid sequences with those of HCMV strain AD169 revealed that there was a high degree of conservation of the epitope between the 33 clinical isolates. However 10 of the isolates possessed silent mutations and three isolates contained mutations producing amino acid changes within the neutralizing epitope. The possible functional significance of these changes is discussed.
Human cytomegalovirus (HCMV) is a herpesvirus which is prevalent throughout the world and usually produces an asymptomatic infection (Onorato et al., 1985; Ho, 1982) . However, in populations that are either imrnunocompromised or have an immature immune system, HCMV infection can lead to a number of clinical manifestations, such as mental retardation in neonates, pneumonitis in transplant recipients (reviewed by Griffiths, 1990 ) and sight-threatening retinitis in AIDS patients (Egbert et al., 1980) . The HCMV genome consists of a linear molecule of dsDNA of 229 354 bp (Chee et al., 1990) which is divided into two regions, the unique long (UL) and the unique short (Us), each of which contains terminal repeat sequences; the genome is reported to encode in excess of 200 proteins (Chee et al., 1990) . Restriction fragment length polymorphism (RFLP) studies have shown that, in the general population, a number of HCMV strains are circulating, each possessing its own restriction profile (for example, Colimon et al., 1985) . Work from several laboratories has exploited this fact to show that the offspring from sequential pregnancies can be infected by the same strain (Huang et al., 1980) and that in renal transplant recipients the donor is the source of HCMV in many cases of disease among initially seropositive recipients (Grundy et al., 1986 (Grundy et al., , 1988 , as well as in seronegative recipients (Wertheim et al., 1983) .
RFLP analysis has contributed to our understanding of strain heterogeneity, however relatively few studies have addressed the question of the variation in proteins among clinical isolates (Zablotney et al., 1978) . At present, neither the biological significance of strain variation nor the role that it may play in the pathogenesis of HCMV is known. Such data will be essential if successful subunit vaccines that protect against all HCMV strains are to be developed.
In this study we have used a combination of RFLP analysis and the polymerase chain reaction (PCR), which was used to amplify a region of the HCMV genome that encodes an amino acid sequence representing a major neutralizing epitope within envelope glycoprotein B (gB or gp58; Utz et al., 1989) . We reasoned that detailed analysis of this region of each clinical isolate at the nucleotide level would provide insight into the extent of strain variation and the effect of antibody pressure on this epitope in vivo, and allow us to assess the possible functional significance of any amino acid alterations discovered in the clinical isolates.
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The clinical HCMV isolates used in this study were derived from patients undergoing renal or bone marrow transplantation in the period 1985 to 1989 and were propagated for one or two passages in primary human embryo lung fibroblasts. One HCMV isolate was derived from a congenitally infected infant (isolate 24) and was analysed prior to passage in fibroblasts. Viral DNA was isolated using the Hirt precipitation method (Hirt, 1967) .
DNA derived from each clinical isolate of HCMV was digested with HindlII and the resulting DNA fragments were resolved by electrophoresis on a 0-7~ agarose gel, Southern-blotted and probed using 32p-labelled, cloned HindlII restriction fragments derived from the UL and Us regions of the HCMV AD169 genome (a gift from Dr P. Greenaway and Dr J. D. Oram, CAMR, Porton, U.K.). PCR amplification was performed on 100 ng of Hirt HCMV DNA essentially as described by Saiki et al. (1988) . The primers used for the PCR amplification were primer 1, 5' GAGGACAAC- (Cranage et al., 1986) . Amplified products (149 bp) were analysed by electrophoresis on a 1-6~ agarose gel containing ethidium bromide, and their authenticity was confirmed by Southern blotting and hybridization with a 32p-labelled AD169 HindlII F probe (Sambrook et al., 1989) . The 149 bp amplified PCR products were cloned into the S m a I site of pT7T3 18U. Both DNA strands of the resulting clones were sequenced according to the plasmid sequencing protocols developed by Murphy & Kavanagh (1989) ; at least three clones were sequenced for PCR products derived from each clinical HCMV isolate to confirm the fidelity of the PCR reaction.
A representative result of the RFLP analyses using radiolabelled cloned HindlII fragments representing the UL and Us regions of the genome in Southern blot analyses is shown in Fig. 1 . This method circumvented problems due to comigrating radiolabelled fragments in the direct analysis of RFLPs. The HindlII restriction profiles of the 28 clinical isolates of HCMV analysed, together with the profiles of the three tissue cultureadapted strains, AD169, Towne and Davis, are shown in Fig. 2 . The RFLP analysis was used to gain a global picture of strain variation within the UL and Us regions of the genome in the clinical samples used prior to detailed DNA sequence analysis of the gB epitope region. For clarity, RFLP analysis of the repeat sequence elements of the genome was not done. The RFLP data showed that in general each specific clinical isolate possessed HindlII sites that were present in at least one of the tissue culture-adapted strains. However, unique HindlII sites were present in six isolates and these Although HindlII polymorphism appears to occur more frequently in certain areas of the genome, similar analysis by ourselves (unpublished data) and other workers using a variety of restriction enzymes have shown that polymorphism is distributed throughout the genome, implying that mutational hot spots do not occur (Colimon et al., 1985) . In the majority of our experiments, the clinical HCMV isolates were subjected to a maximum of two passages in tissue culture after initial inoculation. Although this process will select strains that grow in fibroblast cells, any artefact introduced by continuous passage of the isolate is avoided. In this context, it is interesting to note that only a single HCMV isolate was derived from each of the clinical specimens, whereas HCMV analysed directly from clinical material prior to celt culture passage has been shown to contain multiple strains in certain groups of patients (Chou, 1989; Collier et al., 1989) . However, in this study only one HCMV strain was detected when a specimen obtained from a congenitally infected infant was analysed prior to passage in cell culture.
To gain further insight into the degree of nucleotide sequence variation, we utilized PCR to complement the RFLP analysis. This technique allowed fine structure analysis of a 101 bp region (excluding the primer sequences) of the HCMV genome, which encodes a major neutralizing epitope (amino acids 608 to 626) of gB and is recognized by a murine neutralizing monoclonal antibody (MAb), 7-17 (Utz et al., 1989) . The DNA sequences obtained for the 33 clinical isolates (corresponding to amino acids 603 to 635) were compared with those of AD169 and Towne to reveal the degree of nucleotide variation within the epitope (Fig. 3) . Overall, 20 of the 33 strains exhibited no nucleotide changes within the region encoding amino acids 603 to 635 and the remaining 13 isolates had nucleotide changes ranging from a single base change (isolate 15) to alterations in four bases (isolates 2 and 8).
Translation of these DNA sequences into the primary protein sequence showed that the majority of the single base changes were in the third position of the triplet codon and were therefore silent. However, three clinical strains had changes that led to an alteration in the amino acid sequence of the epitope (Fig. 4) . Isolate 1 had a T-+A transversion in the second position of codon 612, mutating the leucine present in AD169 to a histidine residue, and an A--+T transversion in codon 622, mutating an asparagine to a tyrosine. In isolate 2, a C-+G transversion in the first position of codon 612 resulted in a valine replacing the leucine present in AD169, and in isolate 8 a C--+T transition in the same position of codon 612 resulted in a phenylalanine at this position. It should be noted that both isolates 2 and 8 also exhibited other silent changes. Until the advent of PCR, analysis of intra-strain DNA sequence variation was impractical owing to the limited quantities of the original HCMV DNA. It is interesting to note that all three mutant clinical isolates involved an alteration at leucine 612; however, in one isolate this was due to a change in the second nucleotide of the leucine codon, whereas in the other two isolates the mutation involved the first position of the codon. Given the fact that antibodies directed against the gB molecule can neutralize HCMV infection in vitro (Britt et al., 1988; Gonczol et al., 1986; Rasmussen et al., 1985) and the majority of the total human serum neutralizing activity is directed against gB (Britt et al., 1990) , it is probable that gB is subject to a degree of antibody pressure in vivo. Thus, one interpretation of these observations is that these clinical isolates may represent antibody escape mutants. This possibility is supported by the identification of four amino acid changes in the epitope region with the absence of changes in the flanking sequences. Since some of the amino acid alterations identified are non-conservative, they may be expected to perturb the tertiary structure of the epitope region. Several approaches are available to discern the ramifications of these changes on antibody recognition and virus neutralization by MAb 7-17. First, the original clinical isolates can be propagated and subjected to neutralization assay. At present it has proven impossible to revive these isolates for such analysis to be effected. A second, parallel approach is to use the predicted secondary structures of the AD169 and mutated amino acid sequences to delineate the functional significance of the amino acid alterations. These studies (data not shown) indicate that mutations present in isolates 2 and 8 (leucine 612 to either valine or phenylalanine), and isolate 1 (asparagine 622 to tyrosine) would not be predicted to perturb the structure of the epitope region dramatically. However, the change from leucine to histidine present in isolate 1 would be predicted to cause a significant alteration in the a-helix, made up of residues QLPSL in the AD169 epitope, producing a more pronounced turn conformation. Therefore, these predictions suggest that isolate 1 may be the most likely candidate for a viral strain with reduced susceptibility to neutralization by MAb 7-17. Confirmation of this hypothesis awaits analysis of the neutralization profiles of other clinical isolates containing the same mutation and of a virus specifically engineered by site-directed mutagenesis to contain this mutation. Obviously, the latter approach is required to define fully the residues within this epitope essential for antibody recognition and virus neutralization; such experiments are in progress.
